Sarah P Azad, MD
Obstetrics/Gynecology · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 20
- 5 carriers
- Office
- 1
Offices
1 location · Doctor Azad Medical Corporation · 4 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
20 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Azad’s office at (650) 396-8110 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
20 of 20 plans
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A93504 · Current
Licensed to practise in California · since 2005 · expires 2027-05-31 · Saint Louis University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$2,873
Medicare paid this office $2,873 for 18 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 16 | $2,237 | $118 |
Who their Medicare patients are
18 Original Medicare patients in 2024. Average age 74 · Women 100% · Also on Medicaid 0% · Health risk score 0.72. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
The office billed $11,304, Medicare allowed $3,741 and paid $2,873; for 28 services of 4 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 18 | 28 | 74 | 0.72 | $11,304 | $2,873 |
| 2023 | 12 | 14 | 74 | 0.66 | $5,406 | $1,404 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
Money from drug and device companies
$408 in 2025
| 2025 | 11 | 17 | None | $408 |
| 2024 | 8 | 19 | None | $436 |
| 2023 | 4 | 7 | None | $170 |
| 2022 | 4 | 5 | None | $109 |
| 2021 | 9 | 12 | None | $247 |
| 2020 | 7 | 8 | None | $165 |
| 2019 | 9 | 15 | None | $293 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Astellas Pharma US | Veozah | $76 | 3 payments
|
| Mayne Pharma Commercial | None | $74 | 3 payments
|
| Mentor Worldwide | Mentor Memorygel Resterilizable Gel Sizer | $39 | 1 payment
|
| Sumitomo Pharma America | Myfembree | $36 | 2 payments
|
| Minerva Surgical | None | $35 | 1 payment
|
| Pfizer | Abrysvo | $33 | 2 payments
|
See all 17 published payments
| Sumitomo Pharma America | Meals · 2025-12-18 | Myfembree | $21 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-11-20 | Lynkuet | $21 |
| Mayne Pharma Commercial | Meals · 2025-11-07 | None | $30 |
| Astellas Pharma US | Meals · 2025-10-23 | Veozah | $23 |
| Pfizer | Meals · 2025-08-21 | Abrysvo | $16 |
| CooperSurgical | Meals · 2025-08-14 | Paragard T 380a | $22 |
| Merck Sharp & Dohme | Meals · 2025-07-31 | Gardasil 9 | $25 |
| Biogen | Meals · 2025-07-23 | Zurzuvae | $22 |
| Organon | Meals · 2025-07-10 | Nexplanon | $24 |
| Mayne Pharma Commercial | Meals · 2025-05-15 | None | $23 |
| Pfizer | Meals · 2025-04-24 | Abrysvo | $17 |
| Astellas Pharma US | Meals · 2025-03-19 | Veozah | $30 |
| Minerva Surgical | Meals · 2025-03-11 | None | $35 |
| Sumitomo Pharma America | Meals · 2025-02-11 | Myfembree | $15 |
| Astellas Pharma US | Meals · 2025-02-06 | Veozah | $23 |
| Mayne Pharma Commercial | Meals · 2025-01-22 | None | $21 |
| Mentor Worldwide | Meals · 2025-01-07 | Mentor Memorygel Resterilizable Gel Sizer | $39 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $436
| Astellas Pharma US | Veozah | $162 | 7 payments
|
| Mayne Pharma Commercial | None | $87 | 4 payments
|
| Organon | Nexplanon | $55 | 2 payments
|
| Pfizer | Abrysvo | $46 | 2 payments
|
| Becton Dickinson and | None | $28 | 1 payment
|
| Merck Sharp & Dohme | Gardasil | $25 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Mirena | $17 | 1 payment
|
| Sumitomo Pharma America | Myfembree | $16 | 1 payment
|
2023: $170
| Astellas Pharma US | Veozah | $70 | 3 payments
|
| Mayne Pharma Commercial | None | $54 | 2 payments
|
| CooperSurgical | Paragard T 380a | $25 | 1 payment
|
| Pfizer | Abrysvo | $21 | 1 payment
|
2022: $109
| Mayne Pharma | None | $50 | 2 payments
|
| Evofem Biosciences | Phexxi | $25 | 1 payment
|
| TherapeuticsMD | Annovera | $19 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $16 | 1 payment
|
2021: $247
| Mylan Pharmaceuticals | Xulane | $54 | 3 payments
|
| TherapeuticsMD | Annovera | $43 | 2 payments
|
| AbbVie | Lo Loestrin Fe | $29 | 1 payment
|
| Hologic | Acessa Provu System | $25 | 1 payment
|
| Exeltis USA | Slynd | $22 | 1 payment
|
| Merck Sharp & Dohme | Gardasil 9 | $22 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $19 | 1 payment
|
| Agile Therapeutics | Twirla | $17 | 1 payment
|
| Myriad Genetic Laboratories | Myrisk | $15 | 1 payment
|
2020: $165
| AbbVie | Orilissa | $48 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $22 | 1 payment
|
| Merck Sharp & Dohme | Nexplanon | $22 | 1 payment
|
| Vertical Pharmaceuticals | Osmolex Er | $20 | 1 payment
|
| Exeltis USA | Slynd | $19 | 1 payment
|
| AMAG Pharmaceuticals | Vyleesi | $19 | 1 payment
|
| TherapeuticsMD | Annovera | $14 | 1 payment
|
2019: $293
| TherapeuticsMD | Imvexxy | $86 | 4 payments
|
| AbbVie | Orilissa | $64 | 3 payments
|
| Allergan | Lo Loestrin Fe | $37 | 2 payments
|
| Vertical Pharmaceuticals | Osmolex Er | $21 | 1 payment
|
| Lupin | Solosec | $19 | 1 payment
|
| Merck Sharp & Dohme | Nexplanon | $19 | 1 payment
|
| AMAG Pharmaceuticals | Intrarosa | $16 | 1 payment
|
| Roche Diagnostics | Rs Harmony Test Related Products | $16 | 1 payment
|
| Exeltis USA | Slynd | $15 | 1 payment
|
Professional record
- NPI
- 1457531543
- Licence
- CA A93504California A93504: Current · expires 2027-05-31
- Trained
- Saint Louis University School of Medicine, 2004
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 2495 Hospital Dr Ste 670, Mountain View, CA, 94040
- NPI first listed
- 2007-11-06
- NPI last updated
- 2022-01-26
- NPI record certified
- 2022-01-26
This is when the NPI record was last certified, not a medical board exam.